Group 1: Future Plans in Generic Drug Sector - The company will adhere to a "first generic + fast generic" strategy to develop a diverse product line in the generic drug sector [1] - The company has strong R&D capabilities and a rich pipeline, with plans to enhance investment in existing advantageous products and treatment areas [1] Group 2: R&D Investment and Strategy - The company will continue to increase R&D investment, focusing on clinical needs in major diseases and chronic conditions, employing a combination of generic and innovative research strategies [2] - The company is committed to responding actively to national procurement policies, particularly regarding the 10th round of centralized procurement [2] Group 3: Core Advantages - Cost control is ensured through an integrated approach of "raw materials + formulations," maintaining stable supply [2] - The company has a robust R&D strength with a rich pipeline, continuously enhancing investment in existing advantageous products and treatment areas [2] - A comprehensive sales network has been established, with a professional and efficient sales team focused on market penetration and growth [2]

Group 1: Impact of National Volume Procurement - The company has won bids for 11 products under the national volume procurement policy since its implementation [1] - In the first half of 2024, the company achieved a revenue of 1.655 billion RMB, an increase of 1.58% compared to the same period last year [1] Group 2: R&D Investment - The company focuses its R&D on clinical needs for major diseases and chronic illnesses, employing a strategy that combines innovative and generic development [2] - In the first half of 2024, R&D expenses amounted to 189 million RMB, reflecting a year-on-year growth of 38.19% [2] Group 3: Sales Expense Rate - The company's sales expense rate will be determined based on the bidding and sales performance of individual products [2]

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-10 □特定对象调研 £分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 √其他 反路演 参与单位名称及 新华资产 刘婷 人员姓名 浙商证券 郭双喜 时间 11：30-12：30 地点 双子座大厦 上市公司接待人 员姓名 董事会秘书 李永 投资者关系活动 1.公司 2024 年上半年研发投入情况？ 主要内容介绍 回答：公司研发以重大疾病和慢性病领域临床需求为导向,采 用仿创结合的研发策略，2024 年上半年研发费用为 1.89 亿 元人民币，同比增长 38.19%。 2. 公司 Q2 销售费用率还在下降，24 年预计维持在什么水 平？25-26 年趋势预期？ 回答：公司销售费用要根据各个单品的中标及销售情况确 定，公司搭建了较为全面的销售网络,以产品为中心,组建了专 业、高效的销售队伍进行市场深耕,随着公司产品不断增加,销 售规模扩大,人均销售效率进一步提升。 3. 复方 α-酮酸片集采的预期如何？ 回答：公司会持续关注并积极响应国家集采相关政策。 附 件 清 单 （ 如 有） 日期 2024 年 ...

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-11 □特定对象调研 £分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 √其他 反路演 参与单位名称及 广发基金 李善欣 人员姓名 浙商证券 郭双喜 时间 13：30-14：30 地点 金融大街 9 号金融街中心会议室 上市公司接待人 员姓名 董事会秘书 李永 投资者关系活动 1.公司全年业绩目标如何，较年初计划是否有变动？ 主要内容介绍 回答：2024 年度公司生产经营目标为全年实现营业收入 36.70 亿元，实现利润总额 4 亿元。本预算为公司 2024 年 度经营计划的内部管理控制考核指标，不代表公司 2024 年 盈利预测，仅为公司生产经营计划，能否实现取决于宏观经 济环境、行业发展状况、市场需求、公司管理团队的努力等 诸多因素，具有不确定性，请投资者特别注意。 2. 集采对公司业绩影响？α-酮酸片未来集采冲击评估？ 回答：自国家带量采购政策实施以来,公司先后共有 11 个品 种中标国家带量采购。公司会持续关注并积极响应国家集采 相关政策。 3. 公司仿制药立项的策略？ 回答：公司坚持"临 ...

Group 1: Innovation Drug Development - The company is focusing on the development of innovative drugs, particularly small nucleic acid drugs, and has initiated one non-clinical study [1] - The N-ER platform is based on the company's independent research and development, aimed at discovering and delivering innovative small nucleic acid drugs [2] - The N-ER platform can benchmark against companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals [2] Group 2: Financial Performance - The gross margin for the pharmaceutical formulation and medical device sectors remained stable compared to 2023 [3] - The company's pharmaceutical formulation revenue for the first half of 2024 was approximately ¥1.54 billion [3] - The company plans to disclose its cash dividend ratio for 2024 in accordance with relevant regulations [4] Group 3: Market Strategy and Future Outlook - The company aims to accelerate the consistency evaluation of generic drugs and enter new fields such as innovative drugs and biotherapy [4] - The company is optimistic about the impact of national policies encouraging innovative drugs, which are expected to drive industry development [4] - The company will continue to explore opportunities in the domestic market, particularly in response to emerging demands [4]

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-13 □特定对象调研 £分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 √其他 反路演 参与单位名称及 大家资产 贺晓晗 人员姓名 浙商证券 郭双喜 时间 16：30-17：30 地点 建国门外大街 6 号大家保险中心会议室 上市公司接待人 员姓名 董事会秘书 李永 投资者关系活动 1.公司研发策略及研发投入预期？ 主要内容介绍 回答：公司研发以重大疾病和慢性病领域临床需求为导向,采 用仿创结合的研发策略。公司高度重视研发，将持续加大研 发投入。 2.集采对公司影响？ 回答：自国家带量采购政策实施以来,公司先后共有 11 个品 种中标国家带量采购。公司会持续关注并积极响应国家集采 相关政策。 3.销售费用率预期如何？ 回答：公司销售费用要根据各个单品的中标及销售情况确 定。 附 件 清 单 （ 如 有） 日期 2024 年 8 月 19 日 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [12]. Core Insights - The company reported Q2 results that exceeded expectations, with a revenue of 855 million yuan, a year-on-year increase of 5.20%, and a net profit of 158 million yuan, up 15.69% year-on-year [3][4]. - The improvement in profitability is attributed to the resolution of risks related to the eighth batch of centralized procurement, a decrease in sales expenses, and a continuous enhancement in profit margins [3]. - The gross margin for Q2 was 67.31%, with a net margin of 18.64%, reflecting a year-on-year increase of 1.73 percentage points [3]. - The company has increased its R&D investment, with a R&D expense ratio of 11.44%, up 3.03 percentage points year-on-year, and has received multiple drug registration approvals [3]. Financial Summary - For the first half of 2024, the company achieved a revenue of 1.656 billion yuan, a year-on-year growth of 1.58%, and a net profit of 291 million yuan, up 16.10% year-on-year [3][4]. - The projected revenues for 2024, 2025, and 2026 are 3.588 billion yuan, 3.976 billion yuan, and 4.509 billion yuan, respectively, with year-on-year growth rates of 7.45%, 10.80%, and 13.41% [4][5]. - The forecasted net profits for the same years are 531 million yuan, 621 million yuan, and 714 million yuan, with growth rates of 8.59%, 16.99%, and 15.06% [4][5].

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,655,495,417.22, representing a 1.58% increase compared to CNY 1,629,808,705.94 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was CNY 290,621,292.44, reflecting a 16.10% increase from CNY 250,315,567.56 year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 274,765,305.41, up 12.96% from CNY 243,244,774.92 in the previous year[11]. - The net cash flow from operating activities was CNY 346,233,819.02, an increase of 22.90% compared to CNY 281,722,500.95 in the same period last year[11]. - Basic earnings per share for the first half of the year increased to 0.61 CNY, up 17.31% from 0.52 CNY in the same period last year[12]. - The weighted average return on equity rose to 7.87%, an increase of 0.20 percentage points compared to 7.67% in the previous year[12]. - The total operating profit for the first half of 2024 was CNY 224,974,779.44, compared to CNY 218,015,777.43 in the same period of 2023, reflecting an increase of approximately 3.9%[105]. - The net profit for the first half of 2024 reached CNY 210,278,019.67, up from CNY 191,312,541.92 in the previous year, representing a growth of about 9.9%[106]. - The total comprehensive income for the first half of 2024 was CNY 210,278,019.67, compared to CNY 191,312,541.92 in the same period of 2023, showing a growth of around 9.9%[106]. Assets and Liabilities - The net assets attributable to shareholders of the listed company at the end of the reporting period were CNY 3,375,177,940.94, a decrease of 2.69% from CNY 3,468,416,436.90 at the end of the previous year[11]. - Total assets at the end of the reporting period were CNY 4,436,837,827.38, down 2.44% from CNY 4,547,790,301.79 at the end of the previous year[11]. - The total liabilities and equity at the end of the period were 3,239,007,761.26 RMB, maintaining a balanced financial structure[117]. - The total liabilities rose to ¥719,655,641.28, compared to ¥669,081,598.69 in the previous year, marking an increase of 7.5%[102]. - The total current assets as of June 30, 2024, amounted to CNY 3,090,659,828.55, a decrease from CNY 3,328,740,564.81 as of December 31, 2023, indicating a decline of approximately 7.14%[94]. - Cash and cash equivalents decreased to CNY 1,240,999,787.72 from CNY 2,530,809,346.00, representing a significant drop of about 51.0%[94]. - The total fixed assets as of June 30, 2024, were CNY 677,698,851.17, showing a slight decrease from CNY 678,544,711.16[94]. - Total liabilities decreased to CNY 1,051,719,781.76 from CNY 1,071,251,195.74, a decline of about 1.8%[96]. Research and Development - R&D expenses increased by 38.19% to ¥189,441,111.65, driven by higher investment in R&D projects[26]. - The company focuses on the research and development of drugs and medical devices, with a strong competitive edge and high market recognition[14]. - The company adopts a "仿创结合" (generic and innovative combination) R&D strategy, enhancing its capabilities in drug development[16]. - The company has a strong R&D capability with 320 authorized patents, including 123 invention patents, and 85 projects for generic drug formulations under development[23]. - The company has established a collaborative R&D framework with prestigious universities, enhancing its innovation capabilities[25]. Market and Sales Strategy - The sales model includes both distribution and direct sales, with overseas sales primarily targeting Africa and Southeast Asia[18]. - The company is actively expanding its market presence through nationwide alliances for centralized procurement, aiming to enhance price transparency and fairness across regions[22]. - The company has developed a diverse product pipeline focusing on cardiovascular, chronic kidney disease, skin diseases, digestive system, diabetes, mental health, and gynecology, with 105 products included in the national medical insurance catalog[20]. - The company has been recognized as one of the top 100 pharmaceutical R&D companies in China, reflecting its strong industry position[14]. Environmental Compliance - The company is classified as a key pollutant discharge unit according to environmental protection regulations[40]. - The company has maintained compliance with all environmental discharge standards during the reporting period[44]. - The company has implemented online monitoring for emissions, ensuring real-time compliance with environmental standards[48]. - The company has reported no exceedances in the concentration limits for volatile organic compounds, demonstrating effective emission control measures[49]. - The company generated a total of 62,000 kg of hazardous waste in the first half of 2024, with all waste being disposed of by a qualified unit, Beijing Dingtai Pengyu Environmental Technology Co., Ltd.[45]. Shareholder and Governance - The company has made commitments regarding share transfer restrictions for major shareholders, including a 36-month lock-up period post-IPO[68]. - The controlling shareholder and actual controller committed to avoiding any direct or indirect competition with the company's existing business activities[72]. - The company has disclosed all related party transactions in accordance with regulatory requirements, with no undisclosed transactions existing as of the commitment date[72]. - The company will strictly adhere to information disclosure rules regarding related party transactions[72]. - The company has a total of 24,905 shareholders as of the report date[88]. Financial Reporting and Accounting - The financial statements are prepared based on the going concern assumption, indicating no significant doubts about the company's ability to continue operations for the next 12 months[123]. - The company adheres to the accounting standards for enterprises, ensuring that the financial statements reflect a true and complete picture of its financial status and performance[125]. - The company has established specific accounting policies and estimates for financial instruments impairment, fixed asset depreciation, intangible asset amortization, and revenue recognition[124]. - The company assesses expected credit risk based on historical loss experience, current conditions, and future economic forecasts, calculating expected credit losses through default risk exposure and expected loss rates over the entire duration[139]. Risks and Challenges - The company faces risks related to intensified market competition, particularly if competitors introduce more effective or cost-efficient products[36]. - The company is exposed to risks from national volume-based procurement policies, which could lead to reduced sales prices and impact profitability[36]. - There were no significant risks that materially affected the company's production and operation during the reporting period[2].

一、监事会会议召开情况 证券代码：601089 证券简称：福元医药 公告编号：临 2024-054 北京福元医药股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）审议通过《关于 2024 年半年度募集资金的存放与实际使用情况的专项报告 的议案》 （一）审议通过《关于 2024 年半年度报告及摘要的议案》 监事会认为： (一)公司 2024 年半年度报告的编制和审议程序规范合法，符合法律法规、公司章 程和公司内部管理制度的各项规定，内容真实、准确、完整。 (二)公司 2024 年半年度报告的内容和格式符合中国证监会和上海证券交易所的各 项规定，所包含的信息真实客观反映了公司 2024 年半年度的财务状况和经营成果。 (三)未发现参与 2024 年半年度报告编制和审议的人员存在违反保密规定的行为。 具体内容详见公司披露于上海证券交易所网站的《北京福元医药股份有限公司 2024 年半年度报告》《北京福元医药股份有限公司 2024 年半年度报告摘要》。 表决情况：同意 3 票，反对 0 ...

证券代码：601089 证券简称：福元医药 公告编号：临2024-053 北京福元医药股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 特此公告。 北京福元医药股份有限公司董事会 一、董事会会议召开情况 具体内容详见公司披露于上海证券交易所网站的《北京福元医药股份有限公司 2024 年半年度报告》《北京福元医药股份有限公司 2024 年半年度报告摘要》。本议案已经 董事会审计委员会审议通过，并同意提交董事会审议。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 （二）审议通过《关于 2024 年半年度募集资金的存放与实际使用情况的专项报 告的议案》 具体内容详见公司披露于上海证券交易所网站的《北京福元医药股份有限公司关于 2024 年半年度募集资金的存放与实际使用情况的专项报告》。 北京福元医药股份有限公司（以下简称"公司"）第二届董事会第十二次会议于 2024 年 8 月 2 日以书面及邮件等方式发出会议通知，并于 20 ...